Sort by
Previous Page Page 1 of 20 Next Page
  1. Research

    Cost of diagnosing dementia in a German memory clinic

    Little is known about diagnostic work-ups or the costs of diagnosing dementia in specialized care. Here, we analyzed the costs of diagnosing dementia according to specific dementia disorders.

    Bernhard Michalowsky, Steffen Flessa, Johannes Hertel, Olav Goetz, Wolfgang Hoffmann, Stefan Teipel and Ingo Kilimann

    Alzheimer's Research & Therapy 2017 9:65

    Published on: 22 August 2017

  2. Research

    A coiled conformation of amyloid-β recognized by antibody C706

    β-Amyloid (Aβ) peptide is believed to play a pivotal role in the development of Alzheimer’s disease. Passive immunization with anti-Aβ monoclonal antibodies may facilitate the clearance of Aβ in the brain and ...

    Alexey Teplyakov, Galina Obmolova and Gary L. Gilliland

    Alzheimer's Research & Therapy 2017 9:66

    Published on: 22 August 2017

  3. Review

    Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease

    The specific amyloid-beta (Aβ) species or other amyloid-precursor protein cleavage products that are most directly related to human neurodegeneration and clinical dementia of the Alzheimer’s type have not yet ...

    David L. Brody, Hao Jiang, Norelle Wildburger and Thomas J. Esparza

    Alzheimer's Research & Therapy 2017 9:62

    Published on: 17 August 2017

  4. Research

    Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease

    Mixed vascular and neurodegenerative dementia, such as Alzheimer’s disease (AD) with concomitant cerebrovascular disease, has emerged as the leading cause of age-related cognitive impairment. The brain white m...

    Fang Ji, Ofer Pasternak, Siwei Liu, Yng Miin Loke, Boon Linn Choo, Saima Hilal, Xin Xu, Mohammad Kamran Ikram, Narayanaswamy Venketasubramanian, Christopher Li-Hsian Chen and Juan Zhou

    Alzheimer's Research & Therapy 2017 9:63

    Published on: 17 August 2017

  5. Research

    Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies

    The present study investigated the relationships between thyroid hormone serum levels or thyroid-stimulating hormone (TSH) and two Alzheimer’s disease (AD)-specific biomarkers, cerebral amyloid beta (Aβ) burde...

    Hyo Jung Choi, Min Soo Byun, Dahyun Yi, Bo Kyung Sohn, Jun Ho Lee, Jun-Young Lee, Yu Kyung Kim and Dong Young Lee

    Alzheimer's Research & Therapy 2017 9:64

    Published on: 17 August 2017

  6. Review

    On the path to 2025: understanding the Alzheimer’s disease continuum

    Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clini...

    Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack Jr, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens and Bruno Dubois

    Alzheimer's Research & Therapy 2017 9:60

    Published on: 9 August 2017

  7. Research

    Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?

    Neuropsychological testing is considered crucial for differential diagnosis of Alzheimer’s disease (AD) and behavioural variant frontotemporal dementia (bvFTD). In-depth neuropsychological assessment revealed ...

    Sophia Reul, Hubertus Lohmann, Heinz Wiendl, Thomas Duning and Andreas Johnen

    Alzheimer's Research & Therapy 2017 9:61

    Published on: 9 August 2017

  8. Research

    Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer’s disease

    Diffusion imaging has demonstrated sensitivity to structural brain changes in Alzheimer’s disease (AD). However, there remains a need for a more complete characterization of microstructural alterations occurri...

    Emilie T. Reas, Donald J. Hagler Jr, Nathan S. White, Joshua M. Kuperman, Hauke Bartsch, Karalani Cross, Richard Q. Loi, Akshara R. Balachandra, M. J. Meloy, Christina E. Wierenga, Douglas Galasko, James B. Brewer, Anders M. Dale and Linda K. McEvoy

    Alzheimer's Research & Therapy 2017 9:55

    Published on: 2 August 2017

  9. Research

    Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels

    Increased levels of the pathogenic amyloid β-peptide (Aβ), released from its precursor by the transmembrane protease γ-secretase, are found in Alzheimer disease (AD) brains. Interestingly, monoamine oxidase B ...

    Sophia Schedin-Weiss, Mitsuhiro Inoue, Lenka Hromadkova, Yasuhiro Teranishi, Natsuko Goto Yamamoto, Birgitta Wiehager, Nenad Bogdanovic, Bengt Winblad, Anna Sandebring-Matton, Susanne Frykman and Lars O. Tjernberg

    Alzheimer's Research & Therapy 2017 9:57

    Published on: 1 August 2017

  10. Research

    Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study

    Antidepressant use has been associated with an increased risk of falling, but no studies have been conducted on whether antidepressant use is associated with an increased risk of head injuries which often resu...

    Heidi Taipale, Marjaana Koponen, Antti Tanskanen, Piia Lavikainen, Reijo Sund, Jari Tiihonen, Sirpa Hartikainen and Anna-Maija Tolppanen

    Alzheimer's Research & Therapy 2017 9:59

    Published on: 1 August 2017

  11. Research

    Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders

    Drugs with anticholinergic properties may be associated with various adverse clinical effects. The relationship between the anticholinergic (AC) burden and functional, global cognitive performance and behavior...

    Virginie Dauphinot, Christelle Mouchoux, Sébastien Veillard, Floriane Delphin-Combe and Pierre Krolak-Salmon

    Alzheimer's Research & Therapy 2017 9:58

    Published on: 1 August 2017

  12. Research

    Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

    Neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease with dementia (PDD), and dementia with Lewy bodies (DLB) share clinical and molecular features. Cerebrospinal fluid (CSF) bioma...

    Davide Chiasserini, Leonardo Biscetti, Paolo Eusebi, Nicola Salvadori, Giulia Frattini, Simone Simoni, Naomi De Roeck, Nicola Tambasco, Erik Stoops, Hugo Vanderstichele, Sebastiaan Engelborghs, Brit Mollenhauer, Paolo Calabresi and Lucilla Parnetti

    Alzheimer's Research & Therapy 2017 9:52

    Published on: 28 July 2017

  13. Research

    Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer’s disease pathogenesis

    The apolipoprotein E ε4 (APOE4) genotype is a prominent late-onset Alzheimer’s disease (AD) risk factor. ApoE4 disrupts memory function in rodents and may contribute to both plaque and tangle formation.

    Hoau-Yan Wang, Caryn Trocmé-Thibierge, Andres Stucky, Sanket M. Shah, Jessica Kvasic, Amber Khan, Philippe Morain, Isabelle Guignot, Eva Bouguen, Karine Deschet, Maria Pueyo, Elisabeth Mocaer, Pierre-Jean Ousset, Bruno Vellas and Vera Kiyasova

    Alzheimer's Research & Therapy 2017 9:54

    Published on: 27 July 2017

  14. Research

    Behavioural and neuroanatomical correlates of auditory speech analysis in primary progressive aphasias

    Non-verbal auditory impairment is increasingly recognised in the primary progressive aphasias (PPAs) but its relationship to speech processing and brain substrates has not been defined. Here we addressed these...

    Chris J. D. Hardy, Jennifer L. Agustus, Charles R. Marshall, Camilla N. Clark, Lucy L. Russell, Rebecca L. Bond, Emilie V. Brotherhood, David L. Thomas, Sebastian J. Crutch, Jonathan D. Rohrer and Jason D. Warren

    Alzheimer's Research & Therapy 2017 9:53

    Published on: 27 July 2017

  15. Research

    The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial

    Synaptic dysfunction contributes to cognitive impairment in Alzheimer’s disease and may be countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored wheth...

    Anne Rijpma, Marinette van der Graaf, Marieke M. Lansbergen, Olga Meulenbroek, Aysun Cetinyurek-Yavuz, John W. Sijben, Arend Heerschap and Marcel G. M. Olde Rikkert

    Alzheimer's Research & Therapy 2017 9:51

    Published on: 26 July 2017

  16. Research

    A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism

    CAD-31 is an Alzheimer’s disease (AD) drug candidate that was selected on the basis of its ability to stimulate the replication of human embryonic stem cell-derived neural precursor cells as well as in APPswe/...

    Daniel Daugherty, Joshua Goldberg, Wolfgang Fischer, Richard Dargusch, Pamela Maher and David Schubert

    Alzheimer's Research & Therapy 2017 9:50

    Published on: 14 July 2017

  17. Research

    No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis

    The Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers Aβ1–42, t-tau, and p-tau181 overlap with other diseases. New tau modifications or epitopes, such as the non-phosphorylated tau fraction (p-taurel)...

    Joery Goossens, Maria Bjerke, Hanne Struyfs, Ellis Niemantsverdriet, Charisse Somers, Tobi Van den Bossche, Sara Van Mossevelde, Bart De Vil, Anne Sieben, Jean-Jacques Martin, Patrick Cras, Johan Goeman, Peter Paul De Deyn, Christine Van Broeckhoven, Julie van der Zee and Sebastiaan Engelborghs

    Alzheimer's Research & Therapy 2017 9:49

    Published on: 14 July 2017

  18. Research

    Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults

    This study sought to evaluate gender and APOE genotype-related differences in the concentrations of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and cerebrovascular injury across the life spa...

    Ge Li, Jane B. Shofer, Eric C. Petrie, Chang-En Yu, Charles W. Wilkinson, Dianne P. Figlewicz, Andrew Shutes-David, Jing Zhang, Thomas J. Montine, Murray A. Raskind, Joseph F. Quinn, Douglas R. Galasko and Elaine R. Peskind

    Alzheimer's Research & Therapy 2017 9:48

    Published on: 3 July 2017

  19. Research

    Oligomeric tau-targeted immunotherapy in Tg4510 mice

    Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer’s disease and other tauopathies. Immunotherapy against tau has shown ...

    Sulana Schroeder, Aurelie Joly-Amado, Ahlam Soliman, Urmi Sengupta, Rakiz Kayed, Marcia N. Gordon and David Morgan

    Alzheimer's Research & Therapy 2017 9:46

    Published on: 27 June 2017

  20. Research

    Digitally translated Self-Administered Gerocognitive Examination (eSAGE): relationship with its validated paper version, neuropsychological evaluations, and clinical assessments

    The original paper Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify individuals with mild cognitive impairment (MCI) or early dementia. We e...

    Douglas W. Scharre, Shu ing Chang, Haikady N. Nagaraja, Nicole E. Vrettos and Robert A. Bornstein

    Alzheimer's Research & Therapy 2017 9:44

    Published on: 27 June 2017

  21. Research

    Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse

    Longitudinal studies of dementia with Lewy bodies (DLB) are rare. Clinically, DLB is usually considered to worsen into Alzheimer’s disease (AD). The aim of our study was to compare the rate of the cognitive de...

    Frédéric Blanc, Rachid Mahmoudi, Thérèse Jonveaux, Jean Galmiche, Gilles Chopard, Benjamin Cretin, Catherine Demuynck, Catherine Martin-Hunyadi, Nathalie Philippi, François Sellal, Jean-Marc Michel, Gregory Tio, Melanie Stackfleth, Pierre Vandel, Eloi Magnin, Jean-Luc Novella…

    Alzheimer's Research & Therapy 2017 9:47

    Published on: 27 June 2017

  22. Research

    One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond

    Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway. The in...

    Loïc Dayon, Seu Ping Guiraud, John Corthésy, Laeticia Da Silva, Eugenia Migliavacca, Domilė Tautvydaitė, Aikaterini Oikonomidi, Barbara Moullet, Hugues Henry, Sylviane Métairon, Julien Marquis, Patrick Descombes, Sebastiano Collino, François-Pierre J. Martin, Ivan Montoliu, Martin Kussmann…

    Alzheimer's Research & Therapy 2017 9:43

    Published on: 17 June 2017

  23. Review

    Stem cell models of Alzheimer’s disease: progress and challenges

    A major challenge to our understanding of the molecular mechanisms of Alzheimer’s disease (AD) has been the lack of physiologically relevant in vitro models which capture the precise patient genome, in the cel...

    Charles Arber, Christopher Lovejoy and Selina Wray

    Alzheimer's Research & Therapy 2017 9:42

    Published on: 13 June 2017

Previous Page Page 1 of 20 Next Page